FDA approves topical foam for plaque psoriasis of the scalp and body

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics’ Zoryve (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup